The ocular absorption, elimination and toxicity of 12.5 mg of methotrexate in 0.5 cc administered subconjunctivally was studied in the dog. The purpose of this study was to establish ocular pharmacokinetics for treatment of intraocular tumours in dogs. Drug levels were measured in ocular compartments, and serum at 1,2,4,6,8 and 12 hours respectively. Tumoricidal concentrations of the drug were attained in the anterior chambers of the injected eyes up to and including six hours postinjection. Consistent signs of toxicity were anorexia, vomiting, weight loss and leukopenia. Local ocular toxicity following subconjunctival injection was minimal conjunctival hyperemia lasting up to 48 hours.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1680102PMC

Publication Analysis

Top Keywords

ocular absorption
8
ocular
5
toxicity
4
absorption toxicity
4
toxicity methotrexate
4
methotrexate dog
4
dog ocular
4
absorption elimination
4
elimination toxicity
4
toxicity 125
4

Similar Publications

Laser surgery is recognized as a highly effective method for managing retinal diseases. However, the thermal effects of the laser on different eye tissues are not entirely understood yet. In this context, computational modeling can be a useful tool to predict therapy outcomes.

View Article and Find Full Text PDF

Early stages of diabetic retinopathy are currently considered an unmet medical need due to the lack of effective treatments beyond proper monitoring and control of glycemia and blood pressure. Sitagliptin eye drops have emerged as a new therapeutic approach against early stages of the disease, as they can prevent its main hallmarks, including both neurodegeneration and microvascular impairment. Interestingly, all of these effects occur without any glycemic systemic improvement.

View Article and Find Full Text PDF

Ophthalmologic drugs may be delivered to the eye via a number of ways, including topical drops and gels, intraocular injections, and parenteral or oral administration. The inadvertent systemic absorption of these drugs may lead to a myriad of side effects, ranging from benign cosmetic changes to potentially fatal cardiovascular complications. Historically, glaucoma treatment, including β-blockers and α-agonists, have been particularly examined for such events.

View Article and Find Full Text PDF

Artificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model.

Chin Med J (Engl)

December 2024

Guangzhou National Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong 510530, China.

Background: Retinal ganglion cell (RGC) death caused by acute ocular hypertension is an important characteristic of acute glaucoma. Receptor-interacting protein kinase 3 (RIPK3) that mediates necroptosis is a potential therapeutic target for RGC death. However, the current understanding of the targeting agents and mechanisms of RIPK3 in the treatment of glaucoma remains limited.

View Article and Find Full Text PDF

Ocular diseases have a major impact on patient's vision and quality of life, with approximately 2.2 billion people have visual impairment worldwide according to the findings from the World Health Organization (WHO). The eye is a complex organ with unique morphology and physiology consisting of numerous ocular barriers which hinders the entry of exogenous substances and impedes drug absorption.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!